Biogen (BIIB) Shares Fall as Guidance Comes In Below Consensus, Analyst Says Focus Remains on Aduhelm Coverage

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. PRIM
2. ABBV
3. IBM
4. META
5. MSFT
6. NAVN
7. DFTX
8. CNC
9. KFY
10. SPY

Go back to Biogen (BIIB) Shares Fall as Guidance Comes In Below Consensus, Analyst Says Focus Remains on Aduhelm Coverage

Biogen (BIIB) PT Lowered to $290 at Needham & Company

February 4, 2022 6:26 AM EST

Needham & Company analyst Ami Fadia lowered the price target on Biogen (NASDAQ: BIIB) to $290.00 (from $292.00) while maintaining a Buy rating.

The analyst commented, "BIIB pulled back ~2% following lower-than-expected 2022 guidance as we await visibility into Aduhelm's final coverage decision in April. Irrespective, it... More

Biogen (BIIB) PT Lowered to $304 at Stifel

February 3, 2022 11:12 AM EST

Stifel analyst Paul Matteis lowered the price target on Biogen (NASDAQ: BIIB) to $304.00 (from $344.00) while maintaining a Buy rating following earnings.

The analyst commented, "Biogen's 4Q21 earnings call was fundamentally a non-event, as few specifics were offered on whether there's a feasible... More

Guidance Presents Challenging Set Up for Biogen (BIIB) in 2022 - BMO Capital Markets

February 3, 2022 8:17 AM EST

BMO Capital analyst Evan David Seigerman reiterated an Outperform rating and $260.00 price target on Biogen (NASDAQ: BIIB), following the company's Q4 earnings report.

The analyst quotes: "Guidance represents a challenging set up for 2022with expenses still too high by our view, and not... More